Immunotherapy in patients with metastatic castration-resistant prostate cancer: a meta-analysis of data from 7 phase III studies and 3 phase II studies

BACKGROUND: Immunotherapies have emerged as potential treatments for metastatic castration-resistant prostate cancer (mCRPC). However, it is still unclear to identify the efficacy and safety of immunotherapy in large-scale samples. We performed a meta-analysis of 7 phase III randomized trials and 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Anqiang, Tong, Dali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511714/
https://www.ncbi.nlm.nih.gov/pubmed/36163285
http://dx.doi.org/10.1186/s40164-022-00312-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511714/
https://www.ncbi.nlm.nih.gov/pubmed/36163285
http://dx.doi.org/10.1186/s40164-022-00312-y

Ejemplares similares